Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 171 Cr.
- Current Price ₹ 141
- High / Low ₹ 262 / 104
- Stock P/E 8.62
- Book Value ₹ 100.0
- Dividend Yield 0.00 %
- ROCE 62.0 %
- ROE 60.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.3%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 57.1 days to 82.1 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 87 | 131 | 132 | 203 | 192 | |
| 80 | 120 | 112 | 170 | 165 | |
| Operating Profit | 7 | 11 | 20 | 33 | 27 |
| OPM % | 8% | 9% | 15% | 16% | 14% |
| 0 | 0 | 1 | 2 | 2 | |
| Interest | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 7 | 11 | 19 | 33 | 26 |
| Tax % | 26% | 28% | 28% | 24% | |
| 5 | 8 | 14 | 25 | 20 | |
| EPS in Rs | 40.46 | 58.73 | 102.73 | 26.06 | 18.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 65% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 60% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 |
| Reserves | 5 | 13 | 27 | 44 | 109 |
| 2 | 11 | 12 | 17 | 1 | |
| 17 | 15 | 13 | 16 | 15 | |
| Total Liabilities | 26 | 40 | 54 | 86 | 137 |
| 1 | 6 | 5 | 5 | 5 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 2 |
| 25 | 35 | 49 | 81 | 130 | |
| Total Assets | 26 | 40 | 54 | 86 | 137 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | 5 | -2 | -3 | |
| -1 | -5 | -0 | -0 | |
| 1 | 1 | 3 | 6 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 81 | 62 | 88 | 83 |
| Inventory Days | 10 | 25 | 27 | 50 |
| Days Payable | 65 | 37 | 35 | 26 |
| Cash Conversion Cycle | 25 | 50 | 81 | 107 |
| Working Capital Days | 23 | 25 | 64 | 82 |
| ROCE % | 67% | 62% | 62% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Dec - DRI investigating import classification; INR15.72Cr duty assessed, INR12.78Cr paid, INR2.94Cr to be settled within seven days.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Dec - Virtual investor meeting on 19 Dec 2025 about DRI investigation; no UPSI will be shared.
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
15 Dec - Chairman Ankit Mehta arrested by DRI Dec 11; granted bail Dec 15; customs investigation ongoing.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1 Dec - Of Analyst Meeting to be held on 04th December 2025.
-
Pursuant To Regulation 7(2)(B) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 (PIT Regulations)
25 Nov - Designated person Parul Mehta acquired 9,600 shares (0.08%) on 24 Nov 2025.
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.